Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) have been sharply rising on the charts following the release of encouraging clinical trial results. Its stock price has grown an astounding 130.18% to $3.89 per share as of the most recent pre-market check.
PHIO Shared Clinical Studies Showing Favorable Results
Phio Pharmaceuticals, a clinical-stage biotechnology business, is expanding its range of medications by employing its proprietary INTASYL siRNA gene silencing technology. This strategy aims to improve immune cells’ ability to identify and eliminate cancer cells.
Today, patients in the second cohort of the current Phase 1b clinical research by Phio Pharmaceuticals showed encouraging pathologic responses. Two patients had a full response, indicating 100% tumor removal, according to the data.
Phase 1b Study Progress and Tumor Response Results
The purpose of the Phase 1b clinical research (NCT 06014086) is to assess the safety and tolerability of administering PH-762 intratumorally to patients who have metastatic melanoma, Merkel cell carcinoma, or advanced types of cutaneous squamous cell carcinoma. Of the patients enrolled, six were diagnosed with cutaneous squamous cell carcinoma, and one with metastatic melanoma.
The latest data from the second cohort, which includes four patients, demonstrated significant tumor responses. Two patients with cutaneous squamous cell carcinoma achieved complete tumor clearance, while a third reported a partial response with 90% tumor reduction.
Reassuring Safety Data and Future Outlook
In addition to the encouraging therapeutic responses, the trial has reported no dose-limiting toxicities or clinically significant adverse events. The intratumoral PH-762 injections have been well tolerated, further bolstering the safety profile of the treatment.
Phio Pharmaceuticals is hopeful that more people will sign up for the experiment so that larger dosage concentrations of PH-762 may be tested. The company’s future is bright thanks to these encouraging early dosage escalation findings, as Phio Pharmaceuticals keeps up its revolutionary application of INTASYL technology in pursuit of a cancer-free future.
